On this page
At a glance
Semaglutide is one of the most extensively studied drugs in history. With more than 100 clinical trials, 25,000+ participants in pivotal programs, and FDA approval for multiple indications, the evidence base here is exceptionally strong. This is what robust clinical evidence looks like.
Comprehensive preclinical pharmacology across metabolic, cardiovascular, and hepatic models. Mechanism of action is well-characterized.
One of the most extensively studied drugs in history. Multiple large Phase III RCT programs (SUSTAIN, PIONEER, STEP, SELECT) with 25,000+ total participants. FDA-approved for multiple indications.
Extensive post-marketing surveillance from millions of prescriptions. Well-characterized side effect profile. Known serious risks (pancreatitis, gallbladder disease, thyroid C-cell tumors in rodents) are documented and monitored.
How are these scores calculated?
Semaglutide has the kind of evidence base most peptides can only aspire to: dozens of large randomized controlled trials, tens of thousands of participants, years of post-marketing safety data, and FDA approval for multiple indications. The benefits are real and well-documented. So are the risks and limitations.
New research, delivered clearly
When new studies publish or clinical trials report results, we'll break them down in plain language.
Quick facts
- Molecular weight
- 4,113.58 Da
- Amino acids
- 31 (GLP-1 analog)
- CAS Number
- 910463-68-2
- Developer
- Novo Nordisk (Denmark)
- FDA status
- Approved (Ozempic, Wegovy, Rybelsus)
- WADA status
- Monitoring Program (not prohibited)
Amino acid sequence
[Aib8,Arg34]GLP-1(7-37)-Lys26-C18 fatty diacid
What is semaglutide?
Semaglutide is a synthetic peptide drug that mimics GLP-1 (glucagon-like peptide-1), a hormone your gut naturally releases after eating. It's a 31-amino-acid chain engineered with three specific modifications that extend its half-life from about 2 minutes (native GLP-1) to approximately 7 days — enabling once-weekly dosing.[6]
Developed by Novo Nordisk in Denmark, semaglutide emerged from a systematic program that tested hundreds of GLP-1 analogs. It was compound #217 in that program. The three modifications that make it work are:
- Aib at position 8: Protects against DPP-4 enzyme degradation (what normally destroys GLP-1 in minutes)
- Arg at position 34: Prevents fatty acid binding at an unintended site
- C-18 fatty diacid at Lys26: Enables strong albumin binding, which acts as a slow-release reservoir in the blood
The result is a drug that does what natural GLP-1 does — stimulate insulin release, suppress glucagon, slow stomach emptying, and reduce appetite — but lasts long enough to be clinically useful.
Semaglutide is sold under three brand names: Ozempic (injectable, for type 2 diabetes), Wegovy (injectable and oral, for weight management and MASH), and Rybelsus (oral, for type 2 diabetes). It became a household name around 2022-2023 as its weight loss effects gained widespread media attention.
How it works
In plain terms, semaglutide tells your body three things: release more insulin (but only when blood sugar is already high), slow down digestion so you feel full longer, and reduce appetite signals in the brain. The net effect is lower blood sugar, less hunger, and significant weight loss.
Detailed mechanism (for advanced readers)
Semaglutide is a selective GLP-1 receptor agonist. Its mechanisms of action include:
- Glucose-dependent insulin secretion: Activates GLP-1 receptors on pancreatic beta cells, potentiating insulin release only when glucose is elevated. This glucose-dependent mechanism is why semaglutide alone rarely causes hypoglycemia — a key safety advantage over older diabetes drugs.
- Glucagon suppression: Inhibits glucagon release from pancreatic alpha cells, reducing hepatic glucose production.
- Gastric emptying delay: Slows gastric motility, contributing to both post-prandial glucose reduction and increased satiety. This is also the primary driver of GI side effects (nausea, vomiting).
- Central appetite regulation: Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce appetite and food intake. Recent research (2024) demonstrates semaglutide also modulates dopamine reward signaling, reducing the reward value of food — which may explain its observed effects on food cravings and even alcohol intake.
- Cardiovascular effects: Anti-inflammatory effects on vasculature, reduced atherogenesis, improvements in lipid profiles and blood pressure. These are independent of weight loss, as shown in the SELECT trial.
- Hepatic effects: Reduces hepatic steatosis, inflammation, and fibrosis through mechanisms that include weight loss, improved insulin sensitivity, and direct anti-inflammatory action.
How it differs from related compounds:
- vs. Liraglutide (Victoza/Saxenda): Semaglutide has a longer half-life (weekly vs. daily dosing) and greater weight loss (~15% vs. ~8% body weight).
- vs. Tirzepatide (Mounjaro/Zepbound): Semaglutide is a pure GLP-1 agonist; tirzepatide is a dual GIP/GLP-1 agonist. SURMOUNT-5 showed tirzepatide achieves greater weight loss (-20.2% vs. -13.7%).[11]
- vs. Exenatide (Byetta/Bydureon): Semaglutide is more potent with superior HbA1c reduction and weight loss.
What the research says
Semaglutide has been studied in more than 100 clinical trials with over 25,000 participants in pivotal Phase III programs alone. The evidence for its efficacy in weight loss, glycemic control, and cardiovascular risk reduction is among the strongest in modern medicine.
Research timeline
Semaglutide's research timeline reads like a case study in rigorous drug development — from discovery through multiple FDA approvals and indication expansions:
- 2012Milestone
First Phase III results (SUSTAIN program begins)
Novo Nordisk advances compound #217 (semaglutide) from their GLP-1 analog program into Phase III trials for type 2 diabetes. The SUSTAIN program will eventually include 8 trials.
- 2016Human study
SUSTAIN 6 — cardiovascular benefit demonstrated
Landmark trial of 3,297 patients shows 26% reduction in major cardiovascular events. Semaglutide becomes one of the first diabetes drugs to demonstrate CV protection.
- 2017Regulatory
Ozempic FDA approval (Type 2 diabetes)
FDA approves injectable semaglutide (Ozempic) for type 2 diabetes. The first of several approvals.
- 2019Regulatory
Rybelsus FDA approval (oral, Type 2 diabetes)
The first oral GLP-1 receptor agonist ever approved. A significant pharmaceutical achievement — peptides are notoriously difficult to deliver orally.
- 2021Regulatory
STEP 1 published — 14.9% weight loss; Wegovy approved
STEP 1 trial (n=1,961) demonstrates 14.9% mean weight loss at 68 weeks. FDA approves Wegovy for chronic weight management. Media coverage explodes.
- 2022Human study
Weight regain data published
STEP 1 extension shows participants regain approximately two-thirds of lost weight within one year of stopping semaglutide. A critical finding that reframes obesity as a chronic condition requiring ongoing treatment.
- 2023Human study
SELECT trial — CV benefit in obesity without diabetes
The landmark SELECT trial (n=17,604) demonstrates 20% MACE reduction in obese patients without diabetes. Changes the treatment paradigm for obesity and cardiovascular disease.
- 2024Human study
FLOW trial — kidney protection; WADA monitoring begins
FLOW trial (n=3,533) demonstrates kidney protection in T2D with CKD, stopped early due to clear benefit. WADA places semaglutide on its Monitoring Program.
- 2025Regulatory
ESSENCE trial; MASH approval; oral Wegovy; SOUL trial
ESSENCE trial leads to accelerated FDA approval for MASH (August). Oral Wegovy approved (December). SOUL trial confirms CV benefit for oral semaglutide. Rybelsus gets CV indication expansion (October).
- 2026Regulatory
Compounding restrictions tighten
FDA declares semaglutide shortage officially ended (February). Compounding access restricted. FDA sends 50+ warning letters to GLP-1 compounders. Compounded semaglutide linked to 520 adverse event reports including ~10 deaths.
Key clinical trials
The sheer scale of semaglutide's clinical program is unusual — even among FDA-approved drugs. Here are the most important trials:
STEP 1 — Once-weekly semaglutide in adults with overweight or obesity
Overweight/obesity without type 2 diabetes
14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo. 86.4% of semaglutide participants achieved >=5% weight loss. Published in the New England Journal of Medicine.
SELECT — Cardiovascular outcomes in obesity without diabetes
Overweight/obesity with established cardiovascular disease, without diabetes
20% reduction in major adverse cardiovascular events (HR 0.80, 95% CI 0.72-0.90, p<0.001). The largest CV outcomes trial for an obesity drug ever conducted.
SUSTAIN 6 — Cardiovascular outcomes in type 2 diabetes
Type 2 diabetes at high cardiovascular risk
26% reduction in MACE (HR 0.74, 95% CI 0.58-0.95). First evidence that semaglutide reduces cardiovascular events.
ESSENCE — Semaglutide for MASH (fatty liver disease)
MASH with fibrosis stage 2 or 3
62.9% achieved resolution of steatohepatitis without worsening fibrosis vs. 34.3% placebo at 72 weeks. Led to FDA approval for MASH.
FLOW — Kidney outcomes in type 2 diabetes with CKD
Type 2 diabetes with chronic kidney disease
24% lower risk of primary kidney outcome (HR 0.76, p=0.0003). Trial stopped early due to overwhelming benefit.
STEP 4 — Weight maintenance after withdrawal
Overweight/obesity — weight maintenance
Switching from semaglutide to placebo led to regaining ~two-thirds of prior weight loss within one year. Confirms ongoing treatment is required.
Why this evidence level matters: Compare this to most peptides discussed online. BPC-157 has 3 small human studies with ~30 total participants and no RCTs. Semaglutide has dozens of Phase III trials with tens of thousands of participants. This is the standard that regulatory approval requires — and that consumers should understand when evaluating evidence claims.
Emerging research
Active clinical trials are exploring semaglutide for indications beyond its current approvals:
Emerging indications (ongoing trials)
- Alcohol use disorder / addiction: Epidemiological data and retrospective studies suggest reduced alcohol consumption in semaglutide users. Prospective RCTs are underway.
- Alzheimer's disease / cognitive decline: Early-stage trials investigating potential neuroprotective effects via central GLP-1 receptor activation.
- Polycystic ovary syndrome (PCOS): Pilot studies show improvements in metabolic and reproductive parameters.
- Obstructive sleep apnea: Weight loss improves OSA; semaglutide-specific trials are limited but promising.
- Heart failure: SELECT sub-analyses show benefits for heart failure outcomes.
- Higher-dose formulations: STEP UP program evaluating semaglutide 7.2 mg weekly, showing even greater weight loss than the current 2.4 mg dose.
These are all at various stages of clinical investigation. None have received FDA approval for these specific indications yet.
What the evidence shows
Unlike most peptides profiled on Peptide Garden, the claims about semaglutide are largely supported by strong clinical evidence. Here's the evidence behind the most common questions:
Does semaglutide cause significant weight loss?
This is one of the most well-established drug effects in modern medicine. The STEP program demonstrated 14.9% mean weight loss at 68 weeks (STEP 1), sustained at 15.2% over 2 years (STEP 5). Effects are consistent across populations, including those with type 2 diabetes (9.6%, STEP 2). Higher doses (7.2 mg) show even greater efficacy in STEP UP.
Does semaglutide reduce blood sugar in type 2 diabetes?
Extensively demonstrated across the SUSTAIN (injectable) and PIONEER (oral) programs totaling 18 Phase III trials. HbA1c reductions of 1.0-1.8% depending on dose and comparator. Superior to sitagliptin, exenatide, insulin glargine, and dulaglutide in head-to-head trials.
Does semaglutide reduce cardiovascular risk?
Confirmed in two landmark trials. SUSTAIN 6 (n=3,297) showed 26% MACE reduction in T2D patients. SELECT (n=17,604) showed 20% MACE reduction in obese patients without diabetes. SOUL (n=9,650) confirmed 14% MACE reduction with oral semaglutide. This is FDA-approved indication-level evidence.
Does semaglutide reduce appetite?
Well-established through multiple mechanisms. Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger. Recent research (2024) shows it also modulates dopamine reward signaling, reducing the reward value of food. Patients consistently report reduced hunger and cravings in clinical trials.
Is weight regain a problem after stopping semaglutide?
Yes — this is well-documented. STEP 4 showed that switching from semaglutide to placebo led to regaining approximately two-thirds of prior weight loss within one year. The STEP 1 extension confirmed this pattern. This is not a failure of the drug — it reflects the chronic nature of obesity, similar to how blood pressure returns when you stop taking antihypertensives.
Does semaglutide cause muscle loss?
Weight loss from semaglutide includes 25-40% lean mass loss — consistent with weight loss from any method. The STEP 1 body composition analysis showed total lean body mass decreased by 9.7%, though the lean-to-fat ratio actually improved. The SEMALEAN study found lean mass initially declined but stabilized. Resistance exercise and adequate protein intake can help preserve lean mass.
Can semaglutide treat MASH (fatty liver disease)?
The ESSENCE trial (n=1,197) showed 62.9% resolution of steatohepatitis without worsening fibrosis vs. 34.3% placebo at 72 weeks. FDA granted accelerated approval for MASH with stage F2-F3 fibrosis in August 2025.
Safety & side effects
Semaglutide's safety profile is well-characterized from thousands of patients across dozens of trials, plus post-marketing data from millions of prescriptions. The risks are real — but they are known, documented, and manageable under medical supervision.[7]
Common side effects (from clinical trials)
Gastrointestinal effects are the most common and are dose-dependent:
- Nausea: 20-44% (vs. ~10% placebo) — typically worst during dose escalation, improves over 4-8 weeks
- Diarrhea: 15-30%
- Vomiting: 5-24%
- Constipation: 10-24%
- Abdominal pain: 5-20%
Other reported side effects include injection-site reactions, headache, fatigue, dizziness, and dyspepsia.
Serious safety concerns
Black box warning — Thyroid C-cell tumors: Semaglutide causes dose-dependent thyroid C-cell tumors (including medullary thyroid carcinoma) in rodents. It is unknown whether semaglutide causes thyroid C-cell tumors in humans. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.[14]
- Pancreatitis: Rare but documented. GLP-1 RA users show approximately 2x risk vs. non-users in pharmacovigilance data. Contraindicated in patients with history of pancreatitis.
- Gallbladder disease: Increased risk of cholelithiasis (gallstones), confirmed across multiple trials.
- Acute kidney injury: Reported, likely secondary to dehydration from severe GI side effects. Adequate hydration is essential.
- Diabetic retinopathy: SUSTAIN 6 showed higher rate of retinopathy complications in patients with pre-existing retinopathy.
- Muscle/lean mass loss: 25-40% of weight lost is lean mass. This is a meaningful concern, especially for older adults at risk of sarcopenia.[12]
- Suicidal ideation: Under FDA investigation. A signal was detected in FAERS data, but causation has not been established.
Weight regain after discontinuation
This deserves its own section because it's one of the most important limitations:
- STEP 4: Switching to placebo after 20 weeks of semaglutide led to gradual weight regain[4]
- STEP 1 extension: Participants regained approximately two-thirds of their weight loss within one year of stopping[5]
- Cardiometabolic improvements (blood pressure, lipids, HbA1c) also reversed after discontinuation
This doesn't mean semaglutide "doesn't work." It means obesity is a chronic condition, and semaglutide — like medications for hypertension or high cholesterol — requires ongoing use to maintain its effects.
Contraindications and drug interactions
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Hypersensitivity to semaglutide or excipients
- Pregnancy (teratogenic in animal studies)
Drug interactions:
- Insulin / sulfonylureas: Increased hypoglycemia risk; dose reduction often needed
- Oral medications: Delayed gastric emptying may affect absorption of co-administered drugs
- Warfarin/anticoagulants: More frequent INR monitoring recommended during initiation
- Oral contraceptives: Potential reduced absorption; patients should be counseled accordingly
How people use it
Unlike most peptides profiled on Peptide Garden, semaglutide has FDA-approved dosing protocols validated in large clinical trials. These are the clinically established regimens.
FDA-approved dosing — Ozempic (injectable, type 2 diabetes)
Ozempic dose escalation
FDA-approved dosing — Wegovy (injectable, weight management)
Wegovy dose escalation
FDA-approved dosing — Rybelsus (oral, type 2 diabetes)
Rybelsus dose escalation
Oral administration requires: taking on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before any food or other medications.
Administration routes
- Subcutaneous injection (Ozempic, Wegovy injectable): Abdomen, thigh, or upper arm. Once weekly. Comes in pre-filled pen — no reconstitution needed.
- Oral tablet (Rybelsus, Wegovy oral): Daily for Rybelsus. Approved in oral form for Wegovy as of December 2025.
About the dose escalation schedule: The gradual dose increase exists for a reason — it significantly reduces GI side effects. Skipping escalation steps or starting at a higher dose (as can happen with compounded products) increases the risk of severe nausea and vomiting. This is one of the key safety advantages of FDA-approved products over compounded versions.
Compounded semaglutide: a critical safety distinction
Compounded semaglutide is not the same as FDA-approved semaglutide. The FDA has documented 520 adverse event reports for compounded semaglutide (as of April 30, 2025), including approximately 10 deaths and 100 hospitalizations — primarily from dosing errors. Compounded products may use different salt forms (semaglutide sodium, semaglutide acetate) with unknown pharmacological equivalence. In February 2026, the FDA declared the national semaglutide shortage officially ended, tightening compounding restrictions.[13]
Key differences between FDA-approved and compounded semaglutide:
- Dosing precision: FDA-approved pens deliver exact doses. Compounded vials require manual dose measurement, leading to confusion between mg, mL, and "units" that has caused 5-20x overdoses.
- Salt form: Compounded versions may use semaglutide sodium or acetate, which may have different pharmacological properties than the active ingredient in Ozempic/Wegovy.
- Quality control: FDA-approved products undergo rigorous manufacturing standards. Compounded products have variable quality — the FDA has sent 50+ warning letters to GLP-1 compounders.
- Cost: Compounded semaglutide ($99-$500/month) is significantly cheaper than branded products (Ozempic ~$998/month, Wegovy ~$1,349/month without insurance).
Legal & regulatory status
As of March 2026:
FDA-approved indications
Semaglutide is an FDA-approved prescription drug with multiple approved indications across three brand names:
Compounding status
The regulatory landscape for compounded semaglutide has changed significantly:
- During the FDA-declared shortage, compounding pharmacies could legally prepare semaglutide
- February 2026: The FDA declared the semaglutide shortage officially ended
- Post-shortage, compounding is only permitted for patients with documented medical needs (e.g., allergy to branded inactive ingredients, specific dosing requirements not available in commercial products)
- The FDA has sent 50+ warning letters to GLP-1 compounders for violations
- Tighter restrictions have reduced supply and increased prices at telehealth providers
WADA / USADA status
Semaglutide is not prohibited under WADA anti-doping rules. It has been on WADA's Monitoring Program since 2024, meaning WADA is tracking usage patterns among athletes. Athletes will NOT receive anti-doping violations for semaglutide use. Monitoring continues through 2026 and could potentially result in future prohibition if evidence of performance-enhancing abuse emerges.
Insurance and access
- Most commercial insurance covers semaglutide for the type 2 diabetes indication
- Coverage for weight management is expanding but inconsistent
- Medicare/Medicaid coverage for obesity potentially expanding (April 2026, with a ~$50/month cap)
- Manufacturer savings cards can reduce copays to ~$25/month for eligible commercially insured patients
- Without insurance: Ozempic ~$998/month, Wegovy ~$1,349/month, Rybelsus ~$998/month
How semaglutide compares
Semaglutide vs. Tirzepatide (the most common comparison)
The SURMOUNT-5 trial provided the first head-to-head data between semaglutide and tirzepatide — the two dominant GLP-1-based weight loss drugs:[11]
Semaglutide (Wegovy)
GLP-1 agonist · Novo Nordisk
SURMOUNT-5 weight loss
13.7%
Mechanism
GLP-1 only
Dosing
Weekly SC or daily oral
CV outcomes data
SELECT (n=17,604)
Tirzepatide (Zepbound)
Dual GIP/GLP-1 agonist · Eli Lilly
SURMOUNT-5 weight loss
20.2%
Mechanism
GIP + GLP-1 dual
Dosing
Weekly SC
CV outcomes data
Not yet published
Tirzepatide achieves greater weight loss in head-to-head comparison. However, semaglutide currently has a stronger cardiovascular outcomes evidence base (SELECT trial) and more FDA-approved indications. Both drugs have similar GI side effect profiles. The choice between them is best made with a physician based on individual clinical circumstances.
Semaglutide vs. the peptide evidence standard
To understand what "strong evidence" means, compare semaglutide to a popular research peptide:
Semaglutide
FDA-approved · 3 brand names
Total studies
1,000+
Human trials
100+
FDA status
Approved
First studied
2012
BPC-157
Research compound · Not FDA-approved
Total studies
100+
Human trials
3
FDA status
Category 2
First studied
1991
This contrast isn't meant to diminish BPC-157 — it's meant to calibrate expectations. When you see a peptide vendor claim their product has "clinical evidence," ask: how many participants? What study design? Published where? The difference between 30 participants in open-label studies and 17,604 in a double-blind RCT is the difference between "interesting signal" and "established fact."
Related content
BPC-157 Profile
A useful comparison: BPC-157 has 100+ animal studies but only 3 small human trials. See what different evidence levels look like.
NewsWhat Happened to Peptide Sciences
The largest gray-market peptide vendor shut down. What it means for compounded semaglutide access.
GuideHow to Evaluate a Peptide Clinic
A scorecard for evaluating prescribers and clinics offering semaglutide.
ToolPrice Comparison Worksheet
Compare clinic and compounding pharmacy pricing for semaglutide on a like-for-like basis.
GuideWhat Is 'Ozempic Face'?
The science behind facial volume loss on GLP-1 drugs. What the evidence shows about causes, prevention, and reversibility.
References
- [2]Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. “Semaglutide and cardiovascular outcomes in obesity without diabetes.” N Engl J Med. 2023. 389(24):2221–2232 DOI PubMedRCT
SELECT trial. The largest cardiovascular outcomes trial for an obesity drug: 17,604 participants, mean 33-month follow-up. Changed the treatment paradigm for obesity and CV disease.
- [4]Rubino D, Abrahamsson N, Davies M, et al.. “Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.” JAMA. 2021. 325(14):1414–1425 DOI PubMedRCT
STEP 4 randomized withdrawal trial. 902 participants. Key study demonstrating weight regain after semaglutide discontinuation.
- [5]Wilding JPH, Batterham RL, Davies M, et al.. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension.” Diabetes Obes Metab. 2022. 24(8):1553–1564 DOI PubMedRCT
STEP 1 extension showing two-thirds of weight loss regained within one year of stopping semaglutide.
- [7]Aroda VR, Aberle J, Engel SS, et al.. “Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.” Diabetes Obes Metab. 2023. 25(5):1385–1397 DOI PubMedSystematic review
Pooled safety analysis of 16 Phase IIIa trials, 11,159 patients. The most comprehensive safety review of semaglutide in the literature.
- [8]Sanyal AJ, Newsome PN, et al.. “Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.” N Engl J Med. 2025. 392(21):2089–2099 DOI PubMedRCT
ESSENCE trial. 1,197 patients with MASH. Interim results at 72 weeks led to accelerated FDA approval for MASH indication (August 2025).
- [9]Perkovic V, Tuttle KR, Rossing P, et al.. “Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.” N Engl J Med. 2024. 391(2):109–121 DOI PubMedRCT
FLOW trial. 3,533 participants. Stopped early due to overwhelming benefit. First GLP-1 RA trial with kidney outcomes as primary endpoint.
- [10]Husain M, Bain SC, Jeppesen OK, et al.. “Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes.” N Engl J Med. 2025. 392(16):1534–1548 DOI PubMedRCT
SOUL trial. 9,650 participants. Confirmed 14% MACE reduction with oral semaglutide. Expanded the Rybelsus CV indication (October 2025).
- [12]Ida S, Kaneko R, Murata K. “A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.” Expert Opin Pharmacother. 2024. 25(6):755–766 DOI PubMedSystematic review
Systematic review confirming 25-40% of semaglutide-induced weight loss is lean mass. Highlights the importance of resistance exercise and protein intake.
- [13]U.S. Food and Drug Administration. “FDA's concerns with unapproved GLP-1 drugs used for weight loss.” 2025. Link
FDA safety communication documenting 520 adverse event reports for compounded semaglutide, including ~10 deaths and ~100 hospitalizations from dosing errors.
- [14]Novo Nordisk. “Ozempic (semaglutide) injection — full prescribing information.” 2025. Link
FDA-approved prescribing information. Includes black box warning for thyroid C-cell tumors observed in rodents.
- [15]Novo Nordisk. “Wegovy (semaglutide) injection — full prescribing information.” 2025. Link
FDA-approved prescribing information for weight management, MASH, and CV risk reduction indications.
- [16]Singh G, Krauthamer M, Bjalme-Evans M. “Semaglutide.” StatPearls. 2025. LinkReview
Continuously updated clinical reference covering pharmacology, indications, dosing, and adverse effects.
Medical disclaimer
Peptide Garden is an educational resource, not a medical provider. The information on this page is compiled from published research and FDA-approved prescribing information and is intended for informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Semaglutide is a prescription medication — it should only be used under the supervision of a qualified healthcare provider. Do not start, stop, or change the dose of semaglutide without consulting your doctor.